- MindMed is targeting intriguing psychiatric issues with lucrative markets such as opioid addiction, anxiety, ADHD and cluster headaches.
- Recent partnerships and acquisitions seem promising and bring credible people to support the company.
- Accomplishing announced goals and starting sales is protracted, as the earliest project may enter phase 3 as late as 2024.
- The stock price is bubbly after the recent surge; for that reason I expect falling prices as sentiments cool off and challenges trigger reality checks.
- Long story short, I have a positive outlook on MindMed but will wait for a better buying opportunity.
For further details see:
Mind Medicine: Much Needed Novelty With Inherent Risks And Bubbly Right Now